Despite using the best available assays, 10%–30% of patients with NMO and NMOSD still test negative for AQP4-ab (Granieri et al., 2012; Papadopoulos and Verkman, 2012; Waters et al., 2012). Here, AQP4 is linked to neuromyelitis optica.